Evidence map›Paper›PMID 40767786›Full record

Trial reportThe Journal of clinical psychiatry2025

Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 Trial.

Manish K Jha, Udi E Ghitza, Steve Shoptaw, Abu Minhajuddin, Snoben Kuruvila, Sidarth Wakhlu, Edward V Nunes, Joy Schmitz, Phillip O Coffin, Gavin Bart and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Diagnosis and Treatment of Stimulant-Related Emergencies.Deutsches Arzteblatt international · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Manish K JhaCenter for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.
Udi E GhitzaNational Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Steve ShoptawDepartment of Psychiatry and Biobehavioral Sciences, Department of Family Medicine, University of California Los Angeles, Los Angeles, California.
Abu MinhajuddinCenter for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.
Snoben KuruvilaCenter for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.
Sidarth WakhluCenter for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.
Edward V NunesDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York.
Joy SchmitzDepartment of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center, Houston, Texas.
Phillip O CoffinCenter on Substance Use and Health, San Francisco Department of Public Health, San Francisco, California.
Gavin BartDivision of Addiction Medicine, Hennepin Healthcare, Minneapolis, Minnesota.
Thomas CarmodyCenter for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.
Madhukar H TrivediCenter for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and the Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas.

Funding

Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
Southern Consortium Node of the Clinical Trials Network (Varenicline)UG1DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Kelly S. Barth · 2015 to 2026
$24.8M
Elucidating the Neurocircuitry of Irritability with Ultra-High-Field Neuroimaging to Identify Novel Therapeutic TargetsK23MH126202 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JHA, MANISH KUMAR · 2021 to 2025
$918k
NIDA NIH HHS HHSN271201400028CNIDA NIH HHS HHSN271201500065CNIDA NIH HHS UG1 DA013727NIDA NIH HHS UG1 DA020024NIMH NIH HHS K23 MH126202Wellcome Trust
6 · The paper itself

Abstract

Indexed as

Amphetamine-Related DisordersBupropionDepressionMethamphetamineNaltrexoneAdultDelayed-Action PreparationsDouble-Blind MethodDrug CombinationsDrug Therapy, CombinationFemaleHumansMaleMiddle AgedNarcotic AntagonistsSeverity of Illness IndexBupropionDelayed-Action PreparationsDrug CombinationsMethamphetamineNaltrexoneNarcotic Antagonists

Identifiers

PMID40767786
PMCPMC12798894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.